Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Source: Yahoo Finance
- Acquisition Scale: Eli Lilly announced it will acquire Centessa Pharmaceuticals, a company focused on sleep-wake disorder drugs, for up to $7.8 billion, which is expected to significantly enhance Lilly's market position in sleep medicine.
- Clear Strategic Intent: Through this acquisition, Lilly aims to expand its product portfolio, particularly in the treatment of sleep disorders, to meet the growing market demand and drive future revenue growth.
- Positive Market Reaction: The market reacted positively to the acquisition news, with analysts generally believing that this move will enhance Lilly's innovation capabilities and competitive edge, especially in the rapidly evolving biopharmaceutical industry.
- Financial Impact Assessment: Although the acquisition amounts to $7.8 billion, Lilly anticipates achieving a return on investment in the coming years by integrating Centessa's R&D pipeline and market resources, thereby strengthening its overall financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1065.000
Low
950.00
Averages
1192
High
1500
Current: 1065.000
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Plans to Acquire Three Companies for Nearly $4 Billion
- Acquisition Plans: Eli Lilly announced plans to acquire Curevo, LimmaTech Biologics, and Vaccine Company for nearly $4 billion in cash, with respective deals valued at $1.5 billion, $780 million, and $1.55 billion, indicating a strategic focus on expanding its R&D in infectious diseases.
- Strategic Intent: Chief Scientific Officer Daniel M. Skovronsky stated that these acquisitions reflect a strategy to prevent diseases at their source rather than treating their consequences, highlighting Lilly's proactive approach in public health.
- Curevo's Innovation: Curevo has developed a shingles vaccine for adults, engineered with a synthetic adjuvant to enhance immune system tolerability and reduce side effects, showcasing Lilly's technological prowess in vaccine development.
- Addressing Antimicrobial Resistance: LimmaTech targets bacterial pathogens, including drug-resistant sexually transmitted infections, demonstrating Lilly's commitment to tackling public health challenges and enhancing its competitive position in the market.
See More
Market Dynamics and Investment Opportunities Analysis
- Optimistic Market Outlook: Stock futures are up significantly due to hopes for a peace deal between the U.S. and Iran, with crude oil prices rebounding from morning lows, indicating market sensitivity to geopolitical risks that could affect energy stocks.
- Tech Stock Focus: Analyst recommendations for Dell highlight its advantages in AI infrastructure integration, potentially driving its stock price higher, while Intel's shares have surpassed $120, with expectations of reaching $150, reflecting strong demand in the semiconductor sector.
- Data Storage Industry Prospects: Evercore ISI raised Western Digital's price target to $575, emphasizing the critical role of data storage in the AI ecosystem, and despite its stock rising over 180%, the market still appears to undervalue this sector.
- Software Industry Challenges: Goldman Sachs lowered Workday's price target to $151 due to concerns about its AI integration, reflecting intensified competition in the enterprise software market that could pressure related software stocks.
See More
Eli Lilly Acquires Three Biotech Firms to Expand Infectious Disease Pipeline
- Acquisition Scale: Eli Lilly announced acquisitions of Curevo for up to $1.5 billion, LimmaTech for $780 million, and Vaccine Company for $1.55 billion, demonstrating its ambition in the infectious disease research sector and broadening its business scope.
- Vaccine Development Progress: Curevo is developing Amezosvatein, a shingles vaccine that in Phase 2 studies significantly reduced fatigue, chills, and injection-site pain while matching immune responses to existing treatments, potentially offering a safer market alternative.
- New Technology Platform: LimmaTech Biologics focuses on vaccines against drug-resistant bacterial infections, with its lead candidate currently in Phase 1 testing, which if successful, could provide new solutions for combating diseases like Gonorrhea and Chlamydia, enhancing Lilly's product line.
- Gene Editing Treatment: On Monday, Eli Lilly released early data for Verve-102, a gene-editing treatment designed to permanently lower bad cholesterol, showcasing its potential in cardiovascular health and further solidifying its leadership in the biopharmaceutical industry.
See More
Eli Lilly's VERVE-102 Shows Promising LDL-C Reduction in Early Trials
- Significant Drug Efficacy: Eli Lilly's gene editing candidate VERVE-102 demonstrated a remarkable average reduction of 62% in low-density lipoprotein cholesterol (LDL-C) during early trials, indicating its potential in cardiovascular disease treatment.
- Dose-Dependent Response: In the Phase 1b Heart-2 trial, VERVE-102 showed LDL-C reductions ranging from 9% to 62% at doses of 0.3 mg/kg to 1.0 mg/kg, highlighting a positive correlation between dosage and efficacy.
- Good Safety Profile: The interim analysis of 35 patients indicated mean reductions in PCSK9 levels of 51% to 88% at varying doses, with no treatment-related serious adverse events reported, suggesting a favorable safety and tolerability profile.
- Future Research Plans: Based on these results, Eli Lilly plans to initiate enrollment for a Phase 2 study of VERVE-102 by the end of 2026, aiming to further validate its efficacy in treating patients with heterozygous familial hypercholesterolemia and premature coronary artery disease.
See More
Autozone Faces International Sales Challenges, Stock Drops
- Autozone Sales Decline: Despite strong domestic sales, Autozone CEO Phil Daniele indicated that international sales faced challenges in the latest quarter, resulting in a stock drop of over 5%.
- Financial Performance: Autozone reported third-quarter revenue of $4.84 billion, falling short of the FactSet consensus estimate of $4.86 billion, although earnings per share of $38.07 exceeded expectations of $36.22, indicating relative profitability strength.
- Eli Lilly Acquisition Expansion: Eli Lilly's stock rose 1% after announcing the acquisition of Curevo Inc., LimmaTech Biologics AG, and Vaccine Company to enhance its infectious diseases portfolio, demonstrating the company's intent to expand in the biopharmaceutical sector.
- Lear Corp Rating Upgrade: Lear Corp's stock gained 2% after TD Cowen upgraded its rating from hold to buy, citing the company's strong positioning in North American auto production, with expectations for a stronger market ahead.
See More
Eli Lilly Acquires Three Vaccine Developers for Nearly $4B
- Acquisition of Vaccine Developers: Eli Lilly announced the acquisition of three vaccine developers, Curevo, LimmaTech Biologics, and Vaccine Company, with a total deal value nearing $4 billion, highlighting its strategic focus on infectious disease prevention.
- Curevo Acquisition Details: Lilly will acquire Curevo for up to $1.5 billion in cash, a move that enhances its competitive position in the vaccine market, particularly in shingles vaccine development.
- LimmaTech Deal Terms: The acquisition of LimmaTech is valued at up to $780 million, including undisclosed upfront payments and additional milestone-based payments, aimed at targeting bacterial pathogens such as Staphylococcus aureus.
- Vaccine Company Acquisition Plan: Lilly will also acquire Vaccine Company for up to $1.55 billion in cash, focusing on developing vaccines against the Epstein-Barr virus, further solidifying its investment strategy in the vaccine sector.
See More
Eli Lilly Plans to Acquire Three Companies for Nearly $4 Billion
- Acquisition Plans: Eli Lilly announced plans to acquire Curevo, LimmaTech Biologics, and Vaccine Company for nearly $4 billion in cash, with respective deals valued at $1.5 billion, $780 million, and $1.55 billion, indicating a strategic focus on expanding its R&D in infectious diseases.
- Strategic Intent: Chief Scientific Officer Daniel M. Skovronsky stated that these acquisitions reflect a strategy to prevent diseases at their source rather than treating their consequences, highlighting Lilly's proactive approach in public health.
- Curevo's Innovation: Curevo has developed a shingles vaccine for adults, engineered with a synthetic adjuvant to enhance immune system tolerability and reduce side effects, showcasing Lilly's technological prowess in vaccine development.
- Addressing Antimicrobial Resistance: LimmaTech targets bacterial pathogens, including drug-resistant sexually transmitted infections, demonstrating Lilly's commitment to tackling public health challenges and enhancing its competitive position in the market.
See More
Market Dynamics and Investment Opportunities Analysis
- Optimistic Market Outlook: Stock futures are up significantly due to hopes for a peace deal between the U.S. and Iran, with crude oil prices rebounding from morning lows, indicating market sensitivity to geopolitical risks that could affect energy stocks.
- Tech Stock Focus: Analyst recommendations for Dell highlight its advantages in AI infrastructure integration, potentially driving its stock price higher, while Intel's shares have surpassed $120, with expectations of reaching $150, reflecting strong demand in the semiconductor sector.
- Data Storage Industry Prospects: Evercore ISI raised Western Digital's price target to $575, emphasizing the critical role of data storage in the AI ecosystem, and despite its stock rising over 180%, the market still appears to undervalue this sector.
- Software Industry Challenges: Goldman Sachs lowered Workday's price target to $151 due to concerns about its AI integration, reflecting intensified competition in the enterprise software market that could pressure related software stocks.
See More
Eli Lilly Acquires Three Biotech Firms to Expand Infectious Disease Pipeline
- Acquisition Scale: Eli Lilly announced acquisitions of Curevo for up to $1.5 billion, LimmaTech for $780 million, and Vaccine Company for $1.55 billion, demonstrating its ambition in the infectious disease research sector and broadening its business scope.
- Vaccine Development Progress: Curevo is developing Amezosvatein, a shingles vaccine that in Phase 2 studies significantly reduced fatigue, chills, and injection-site pain while matching immune responses to existing treatments, potentially offering a safer market alternative.
- New Technology Platform: LimmaTech Biologics focuses on vaccines against drug-resistant bacterial infections, with its lead candidate currently in Phase 1 testing, which if successful, could provide new solutions for combating diseases like Gonorrhea and Chlamydia, enhancing Lilly's product line.
- Gene Editing Treatment: On Monday, Eli Lilly released early data for Verve-102, a gene-editing treatment designed to permanently lower bad cholesterol, showcasing its potential in cardiovascular health and further solidifying its leadership in the biopharmaceutical industry.
See More
Eli Lilly's VERVE-102 Shows Promising LDL-C Reduction in Early Trials
- Significant Drug Efficacy: Eli Lilly's gene editing candidate VERVE-102 demonstrated a remarkable average reduction of 62% in low-density lipoprotein cholesterol (LDL-C) during early trials, indicating its potential in cardiovascular disease treatment.
- Dose-Dependent Response: In the Phase 1b Heart-2 trial, VERVE-102 showed LDL-C reductions ranging from 9% to 62% at doses of 0.3 mg/kg to 1.0 mg/kg, highlighting a positive correlation between dosage and efficacy.
- Good Safety Profile: The interim analysis of 35 patients indicated mean reductions in PCSK9 levels of 51% to 88% at varying doses, with no treatment-related serious adverse events reported, suggesting a favorable safety and tolerability profile.
- Future Research Plans: Based on these results, Eli Lilly plans to initiate enrollment for a Phase 2 study of VERVE-102 by the end of 2026, aiming to further validate its efficacy in treating patients with heterozygous familial hypercholesterolemia and premature coronary artery disease.
See More
Autozone Faces International Sales Challenges, Stock Drops
- Autozone Sales Decline: Despite strong domestic sales, Autozone CEO Phil Daniele indicated that international sales faced challenges in the latest quarter, resulting in a stock drop of over 5%.
- Financial Performance: Autozone reported third-quarter revenue of $4.84 billion, falling short of the FactSet consensus estimate of $4.86 billion, although earnings per share of $38.07 exceeded expectations of $36.22, indicating relative profitability strength.
- Eli Lilly Acquisition Expansion: Eli Lilly's stock rose 1% after announcing the acquisition of Curevo Inc., LimmaTech Biologics AG, and Vaccine Company to enhance its infectious diseases portfolio, demonstrating the company's intent to expand in the biopharmaceutical sector.
- Lear Corp Rating Upgrade: Lear Corp's stock gained 2% after TD Cowen upgraded its rating from hold to buy, citing the company's strong positioning in North American auto production, with expectations for a stronger market ahead.
See More
Eli Lilly Acquires Three Vaccine Developers for Nearly $4B
- Acquisition of Vaccine Developers: Eli Lilly announced the acquisition of three vaccine developers, Curevo, LimmaTech Biologics, and Vaccine Company, with a total deal value nearing $4 billion, highlighting its strategic focus on infectious disease prevention.
- Curevo Acquisition Details: Lilly will acquire Curevo for up to $1.5 billion in cash, a move that enhances its competitive position in the vaccine market, particularly in shingles vaccine development.
- LimmaTech Deal Terms: The acquisition of LimmaTech is valued at up to $780 million, including undisclosed upfront payments and additional milestone-based payments, aimed at targeting bacterial pathogens such as Staphylococcus aureus.
- Vaccine Company Acquisition Plan: Lilly will also acquire Vaccine Company for up to $1.55 billion in cash, focusing on developing vaccines against the Epstein-Barr virus, further solidifying its investment strategy in the vaccine sector.
See More
